Heart Failure Wired from Shock to Devices and Home: A New Era of Delivery

Q: What is the clinical evidence from this study?

Study design: Editorial. Population: Heart failure. Intervention: Heart failure therapies.

Amin Yehya; Melvin R Echols

doi:10.15420/usc.2026.07

May 14, 2026US Cardiology ReviewOpen Access

Heart Failure Wired from Shock to Devices and Home: A New Era of Delivery

View Full Paper

Ask AI

Bookmark

Share

Figures

Key Points

To review the evolving landscape of heart failure management across the care continuum, spanning intensive cardiogenic shock interventions, chronic device monitoring, targeted pharmacotherapies, and real-world implementation challenges.
Synthesized clinical trial findings and management paradigms across five clinical domains spanning the trajectory from the intensive care unit to outpatient and home care.
Evaluated evidence for cardiogenic shock protocols, implantable congestion sensors, transcatheter valve therapies, cardiometabolic pharmacotherapy, and genotype-directed amyloidosis treatments.
Device and structural interventions demonstrated efficacy, including a 39% reduction in heart failure hospitalizations with CardioMEMS in the CHAMPION trial and improved 1-year hierarchical composite outcomes with transcatheter tricuspid valve replacement in TRISCEND II (win ratio = 2.02).
Cardiometabolic agents improved major outcomes, with dapagliflozin reducing worsening heart failure or cardiovascular death by 26% in DAPA-HF and empagliflozin reducing cardiovascular death and first heart failure hospitalization by 21% in EMPEROR-Preserved.
Targeted ATTR-CM therapies significantly lowered clinical endpoints, including reduced all-cause mortality with tafamidis (HR 0.70), composite endpoint improvements with acoramidis in ATTRibute-CM (win ratio = 1.8), and reduced mortality and recurrent cardiovascular events with vutrisiran in HELIOS-B (HR 0.72).

PICO

P

Population

Heart failure

I

Intervention / Comparator

Heart failure therapies

Limitations

Challenges in workflow, site-based trial execution, and implementation of findings hinder ongoing HF optimization
Clinical inertia remains a challenge to optimize SGLT-2 inhibitor use
Persistent gaps in HF care regarding effective communication and health literacy assessment

Implication

Does not support changing HF care delivery yet; hypothesis-generating for device and home monitoring innovations.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Yehya et al. (2026) conducted an editorial in Heart failure. Heart failure therapies was evaluated.

synapsesocial.com/papers/6a6164ebc26d28d1bc3f3f98 https://doi.org/10.15420/usc.2026.07

View Full Paper

Ask AI

Bookmark

Share

Heart Failure Wired from Shock to Devices and Home: A New Era of Delivery

Figures

Key Points

PICO

Limitations

Implication

Abstract

Discussion

Cite This Study

Heart Failure Wired from Shock to Devices and Home: A New Era of Delivery

Figures

Key Points

PICO

Limitations

Implication

Abstract

Discussion

Cite This Study

Keep reading

More related papers

More from US Cardiology Review

Keep reading

More related papers

More from US Cardiology Review